A61K 47/551
One of the codrug's components being a vitamin
Official title: {one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid}
A61K47/551 (One of the codrug's components being a vitamin) appears on 361 US grants and 722 published applications in this corpus.
Search patents in A61K- Granted patents
- 361
- Published applications
- 722
- Assignees
- 376
- Inventors
- 1,311
- Latest grant
- 21 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 1 | 0 |
| 1996 | 2 | 0 |
| 1997 | 3 | 0 |
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 1 | 0 |
| 2001 | 0 | 1 |
| 2002 | 1 | 4 |
| 2003 | 0 | 10 |
| 2004 | 1 | 9 |
| 2005 | 3 | 17 |
| 2006 | 5 | 13 |
| 2007 | 5 | 15 |
| 2008 | 1 | 16 |
| 2009 | 9 | 16 |
| 2010 | 6 | 30 |
| 2011 | 10 | 28 |
| 2012 | 19 | 23 |
| 2013 | 18 | 37 |
| 2014 | 16 | 32 |
| 2015 | 16 | 28 |
| 2016 | 24 | 35 |
| 2017 | 22 | 35 |
| 2018 | 21 | 35 |
| 2019 | 24 | 39 |
| 2020 | 30 | 51 |
| 2021 | 23 | 39 |
| 2022 | 23 | 52 |
| 2023 | 18 | 42 |
| 2024 | 25 | 46 |
| 2025 | 20 | 47 |
| 2026 | 12 | 22 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Nano-assemblies of conjugates of retinoids and amino acids21 Jul 2026US 12,685,778 B2
- Filamentous nanostructures and their use for treatment of pulmonary disease2 Jun 2026US 12,642,860 B2The Johns Hopkins University
- Polypeptide formulations comprising crystal or amorphous polypeptides and vitamin E26 May 2026US 12,636,257 B2Bhami's Research Laboratory, Pvt. Ltd.
- Pharmaceutical composition for preventing or treating atopic disease containing Akkermansia muciniphila strain26 May 2026US 12,636,319 B2Enterobiome Inc.
- Rejuvenation of CAR T cell12 May 2026US 12,622,973 B2Purdue Research Foundation
- A combination therapy for cancer treatment8 Oct 2026US 2026/0306633 A1Purdue Research Foundation
- Universal abt compounds and uses thereof24 Sep 2026US 2026/0284204 A1Kleo Pharmaceuticals, Inc.
- Enhancing brain permeability and activity of glucosylceramidase (gcase) prosna for neurodegenerative diseases6 Aug 2026US 2026/0224711 A1Northwestern University
- Co-drug, co-administration, and sequential administration of selective ttr ligand and c20-d3-retinol for elimination of mechanism-based ocular adverse effects in treating macular degeneration and ttr amyloidosis30 Jul 2026US 2026/0216177 A1Rensselaer Polytechnic Institute
- Small molecule-drug-conjugates cleavable in a tumor microenvironment2 Jul 2026US 2026/0183405 A1
Most cited
By later US patents
- Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof518US 5,550,111 ATemple University of the Commonwealth System of Higher Education · 1996
- Method for enhancing transmembrane transport of exogenous molecules352US 5,416,016 APurdue Research Foundation · 1995
- Lipid formulation340US 8,158,601 B2Alnylam Pharmaceuticals, Inc. · 2012
- Method for enhanced transmembrane transport of exogenous molecules302US 5,108,921 APurdue Research Foundation · 1992
- Site specific delivery of nucleic acids by combining targeting ligands with endosomolytic components256US 9,345,780 B2Tekmira Pharmaceuticals Corporation · 2016